文献速递骨质疏松与钙磷/甲状旁腺

甲状旁腺腺瘤经皮消融:系统评价与Meta分析

Percutaneous Ablation of Parathyroid Adenomas: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该系统评价与Meta分析纳入20项研究共815例患者,评估经皮消融治疗甲状旁腺腺瘤的有效性与安全性。结果显示消融后6至12个月血糖正常率为85.6%(95%CI,80.48-90.72),血清PTH和钙水平显著下降,永久性声音嘶哑和主要并发症发生率低,射频、微波与乙醇消融疗效安全性相当。

要点

  • 消融后6至12个月血糖正常率为85.6%(95%CI,80.48-90.72)。
  • 血清PTH平均下降101.49 pg/mL(95%CI,73.50-129.48),钙平均下降0.39 mmol/L(95%CI,0.34-0.45)。
  • 永久性声音嘶哑发生率0.28%(95%CI,0.00-1.05),主要并发症0.31%(95%CI,0.00-1.09),射频、微波与乙醇消融相当。

核心结论

  • 经皮消融治疗甲状旁腺腺瘤在治疗后第一年内安全有效。
  • 射频、微波与乙醇消融技术可根据患者需求选用,无特定限制。

研究设计与样本

  • 遵循系统评价与Meta分析优先报告条目(PRISMA)指南,系统检索Ovid MEDLINE和Cochrane等多个数据库。
  • 纳入提供射频消融、微波消融和乙醇消融技术单独数据的研究,共20项研究、815例患者。
  • 采用随机效应模型合并数据,计算合并患病率和95%CI,并用Egger检验评估发表偏倚。

主要发现

  • 消融后6至12个月血糖正常率为85.6%(95%CI,80.48-90.72)。
  • 血清PTH平均下降101.49 pg/mL(95%CI,73.50-129.48),血清钙平均下降0.39 mmol/L(95%CI,0.34-0.45)。
  • 永久性声音嘶哑发生率为0.28%(95%CI,0.00-1.05),主要并发症发生率为0.31%(95%CI,0.00-1.09)。
  • 射频、微波和乙醇消融的安全性和有效性结局相当。

关键数值与推荐

  • 血糖正常率定义为消融后6至12个月血清钙正常。
  • 安全性结局包括暂时性声音嘶哑、永久性声音嘶哑、严重出血、主要并发症和严重低钙血症。

临床怎么用

  • 作者认为经皮消融治疗甲状旁腺腺瘤在治疗后第一年内安全有效。
  • 作者建议射频、微波和乙醇消融技术可根据患者需求选用,无特定限制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Percutaneous ablation of parathyroid adenomas provides a minimally invasive treatment option for primary hyperparathyroidism. However, the overall performance of this technique remains underexplored. This meta-analysis evaluates the effectiveness and safety of various ablation techniques for parathyroid adenomas. METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, multiple databases, including Ovid MEDLINE and Cochrane, were systematically searched. Studies that provided separate data for radiofrequency (RF), microwave ablation (MWA), and ethanol ablation technique were included. Outcomes of interest were changes in serum calcium, PTH, and phosphorus levels, along with normocalcemia rates at 6 to 12 months after ablation. Safety outcomes included transient hoarseness, permanent hoarseness, severe hemorrhage, major complications, and severe hypocalcemia. Data were pooled using a random-effects model, with pooled prevalence and 95% CIs calculated. Also, the publication bias was assessed with Egger's test for each outcome measure. RESULTS: Twenty studies (815 patients) were included. The posttreatment normocalcemia rate at 6 to 12 months was 85.6% (95% CI, 80.48-90.72). Serum PTH and calcium levels significantly decreased, with mean differences of 101.49 pg/mL (95% CI, 73.50-129.48) and 0.39 mmol/L (95% CI, 0.34-.45), respectively. Permanent hoarseness and major complications were rare, with incidences of 0.28% (95% CI, 0.00-1.05) and 0.31% (95% CI, 0.00-1.09). The safety and efficacy outcomes of RF, MWA, and ethanol ablation were comparable. CONCLUSION: Our findings indicate that percutaneous ablation of parathyroid adenomas is safe and effective within the first year of the treatment. Additionally, they suggest that RF, MWA, and ethanol ablation techniques can each be employed depending on patients' needs without particular limitations.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bilgin C, Hibbert R, Oztepe F, et al. Percutaneous Ablation of Parathyroid Adenomas: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2025. PMID: 40326768. doi:10.1210/clinem/dgaf270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。